David Surguladze is an experienced leader in preclinical pharmacology and non-clinical development, currently serving as the Vice President and Head of Non-Clinical Development at LifeMine Therapeutics since September 2024. Prior to this role, David held the position of Vice President of Preclinical Pharmacology at HiberCell from March 2019 to November 2023. David's career includes significant tenures at Eli Lilly and Company, where responsibilities ranged from Director to Associate Director in Preclinical Pharmacology from June 2010 to February 2019, and at ImClone Systems, serving as Group Leader and Senior Scientist III from October 2004 to June 2010. David began the professional journey at Nobex Corporation as a Senior Scientist from 1998 to 2004.